These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 20606453)

  • 41. Symptomatic treatment of neurologic symptoms in Wilson disease.
    Litwin T; Dušek P; Członkowska A
    Handb Clin Neurol; 2017; 142():211-223. PubMed ID: 28433105
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Movement disorders in adult patients with classical galactosemia.
    Rubio-Agusti I; Carecchio M; Bhatia KP; Kojovic M; Parees I; Chandrashekar HS; Footitt EJ; Burke D; Edwards MJ; Lachmann RH; Murphy E
    Mov Disord; 2013 Jun; 28(6):804-10. PubMed ID: 23400815
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Medical treatment of dystonia.
    Jankovic J
    Mov Disord; 2013 Jun; 28(7):1001-12. PubMed ID: 23893456
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Wilson disease: neurologic features.
    Członkowska A; Litwin T; Chabik G
    Handb Clin Neurol; 2017; 142():101-119. PubMed ID: 28433096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Temporal characteristics of botulinum neurotoxin therapy.
    Lebeda FJ; Cer RZ; Stephens RM; Mudunuri U
    Expert Rev Neurother; 2010 Jan; 10(1):93-103. PubMed ID: 20021324
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Historical note on the therapeutic use of botulinum toxin in neurological disorders.
    Erbguth FJ
    J Neurol Neurosurg Psychiatry; 1996 Feb; 60(2):151. PubMed ID: 8708643
    [No Abstract]   [Full Text] [Related]  

  • 47. [Effects of high-dosage trihexyphenidyl on symptomatic dystonia in a case of Wilson disease].
    Hirabayashi S; Kanda H; Tsuno T; Akabane T; Oguchi K; Yanagisawa N
    No To Hattatsu; 1985 Nov; 17(6):571-6. PubMed ID: 4084421
    [No Abstract]   [Full Text] [Related]  

  • 48. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
    Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EASL Clinical Practice Guidelines: Wilson's disease.
    European Association for Study of Liver
    J Hepatol; 2012 Mar; 56(3):671-85. PubMed ID: 22340672
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Study of Dopaminergic Pathway in Neurologic Wilson Disease with Movement Disorder.
    Kalita J; Tripathi A; Jadhav M; Thakur RS; Patel DK
    Mol Neurobiol; 2023 Jun; 60(6):3496-3506. PubMed ID: 36879138
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gandouling Mitigates CuSO
    Fang S; Yang W; Zhang K; Peng C
    Animals (Basel); 2022 Oct; 12(19):. PubMed ID: 36230444
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of High-Frequency Repetitive Transcranial Magnetic Stimulation on Upper Limb Dystonia in Patients With Wilson's Disease: A Randomized Controlled Trial.
    Hao W; Wei T; Yang W; Yang Y; Cheng T; Li X; Dong W; Jiang H; Qian N; Wang H; Wang M
    Front Neurol; 2021; 12():783365. PubMed ID: 34970214
    [No Abstract]   [Full Text] [Related]  

  • 53. Chelation therapy in liver diseases of childhood: Current status and response.
    Seetharaman J; Sarma MS
    World J Hepatol; 2021 Nov; 13(11):1552-1567. PubMed ID: 34904029
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effective Treatment of Neurological Symptoms with Normal Doses of Botulinum Neurotoxin in Wilson's Disease: Six Cases and Literature Review.
    Hefter H; Samadzadeh S
    Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33805281
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biochemical Markers for the Diagnosis and Monitoring of Wilson Disease.
    Mohr I; Weiss KH
    Clin Biochem Rev; 2019 May; 40(2):59-77. PubMed ID: 31205375
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current anti-copper therapies in management of Wilson disease.
    Mohr I; Weiss KH
    Ann Transl Med; 2019 Apr; 7(Suppl 2):S69. PubMed ID: 31179306
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical management of Wilson disease.
    Hedera P
    Ann Transl Med; 2019 Apr; 7(Suppl 2):S66. PubMed ID: 31179303
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Wilson's Disease: Clinical Practice Guidelines of the Indian National Association for Study of the Liver, the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition, and the Movement Disorders Society of India.
    Nagral A; Sarma MS; Matthai J; Kukkle PL; Devarbhavi H; Sinha S; Alam S; Bavdekar A; Dhiman RK; Eapen CE; Goyal V; Mohan N; Kandadai RM; Sathiyasekaran M; Poddar U; Sibal A; Sankaranarayanan S; Srivastava A; Thapa BR; Wadia PM; Yachha SK; Dhawan A
    J Clin Exp Hepatol; 2019; 9(1):74-98. PubMed ID: 30765941
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characteristics of a newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilson's Disease Rating Scale.
    Członkowska A; Litwin T; Dzieżyc K; Karliński M; Bring J; Bjartmar C
    BMC Neurol; 2018 Apr; 18(1):34. PubMed ID: 29621974
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dystonic Dysarthria in Wilson Disease: Efficacy of Zolpidem.
    Poujois A; Pernon M; Trocello JM; Woimant F
    Front Neurol; 2017; 8():559. PubMed ID: 29163329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.